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Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with marked variability 
in the clinical course. The disease is also characterized by the presence of a genetical 
heterogeneity that is becoming apparent through studies of immunoglobulin heavy 
chain gene, chromosomal aberrations, microRNA deregulation and genetic 
abnormalities identified by whole genome sequencing. Furthermore, a strong 
relationship between specific genetic aberrations and the clinical course of CLL is 
observed. 
Recent advances in genomics have transformed the research on hematologic 
malignancies by improving molecular approaches to gene networks. The recognition of 
novel molecular variables identified by the use of high-throughput molecular analytical 
techniques could contribute to a better knowledge of the pathogenesis of the disease 
and to the development of more accurate biological predictive factors. Thus 
microarrays have emerged as powerful tools for increasing the potential of standard 
methods through genome-wide biological studies. Array-CGH analysis has shown great 
promise as a tool for the analysis of genetic alterations in complex cancer genomes 
providing, in a single experiment, a general view of genomic gains and losses. 
Therefore the use of aCGH may detect new genetic lesions in CLL. Microarray 
expression profiling of CLL has been used to define the patterns of gene expression 
related to different clinical outcomes and chromosomal abnormalities. The global 
views of gene expression, when coupled with available knowledge about gene 
function, also provide the basis for formulating testable hypothesis about specific 
cellular pathways of CLL. Moreover, recently, the application of next generation 
sequencing technology has identified previously unknown recurrent mutations in CLL.  
 
The general aim of this thesis was to analyze and to characterize the heterogeneity of 
CLL patients by applying high-throughput genomic technologies to gain knowledge in 
the molecular characteristics of CLL and their possible influence on the disease. The 
first part of this thesis contains a general introduction of the field, including the basics 
of the techniques applied for genomic profiling and next-generation sequencing, and 
different aspects of CLL. The second section specifies the goals of the thesis and shows 


































Original papers  
 
This thesis is based on the following papers, which in the text are referred to by their 
roman numerals:  
I. Rodríguez AE, Robledo C, García JL, González M, Gutiérrez NC, Hernández JA, 
Sandoval V, García de Coca A, Recio I, Risueño A, Martín-Núñez G, García E, 
Fisac R, Conde J, de Las Rivas J, Hernández JM. Identification of a novel 
recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH 
and gene expression profiling. Ann Oncol. 2012 Jan 6. [Epub ahead of 
print]. 
 
II. Hernández JA*, Rodríguez AE*, González M, Benito R, Fontanillo C, Sandoval V, 
Romero M, Martín-Núñez G, de Coca AG, Fisac R, Galende J, Recio I, Ortuño 
F, García JL, de las Rivas J, Gutiérrez NC, San Miguel JF, Hernández JM. 
A high number of losses in 13q14 chromosome band is associated with a 
worse outcome and biological differences in patients with B-cell chronic 
lymphoid leukemia. Haematologica. 2009 Mar;94(3):364-71. 
*shared first authorship 
 
III. Rodríguez AE, Hernández JA, Benito R, Gutiérrez NC, García JL, Hernández-
Sánchez M, Risueño A, Sarasquete ME, Fermiñán E, Fisac R, García de Coca 
A, Martín-Núñez G, de las Heras N, Recio I, Gutiérrez O, de las Rivas J, 
González M, Hernández-Rivas JM. Molecular characterization of chronic 
lymphocytic leukemia patients with a high number of losses in 13q14. 
Submitted. 
 
IV. Rodríguez AE, Quwaider D, Benito R, Misiewicz-Krzeminska I, Hernández-
Sánchez M, Rojas-Ricardo E, Sarasquete ME, Gutiérrez NC, Hernández-Rivas 
JM. A common polymorphism in 3´UTR deregulates HSP90B1 expression in 

























Since 1956, when Tjio and Levan made the landmark observation that human cells 
contain 46 chromosomes, the practice of cytogenetics has witnessed many 
innovations, including chromosome banding techniques, fluorescence in situ 
hybridization (FISH), spectral karyotyping, and comparative genomic hybridization 
(CGH).1 Of these advances, G-banded karyotyping has been the most useful method in 
routine   studies and has hence been the gold standard for analyzing chromosomes for 
the past several decades. In CLL, the use of Fluorescence “in situ” hybridization also 
provided new genetic markers and became an available tool in clinical setting. These 
advances helped to elucidate the causes of a range of genetic disorders and cancers, 
and the experts in the field formulated criteria for their use in clinical diagnostics. The 
most recent microarray-based CGH (array CGH), offered a method for whole-genome 
analysis at resolutions much greater than that possible with conventional karyotyping.2 
The first genomic microarray technique for detecting DNA alterations, array 
comparative genomic hybridization (aCGH), was developed from conventional CGH in 
the late 1990´s.3,4 This methodology is based on the detection of CNAs due to a higher 
or lower ratio of inbound differently labeled sample DNA compared to a reference 
DNA (Figure 1). Instead of metaphase chromosomes acting as targets for sample DNA 
binding, aCGH uses thousands of short DNA probes, each representing a unique part of 
the genome, arrayed onto for example a glass slide. The fluorescence for each probe is 
recorded separately for the sample and reference channel using a laser scanner, and 
the formed ratio (sample/reference) can be plotted against the known genomic 
positions of each probe generating a high-resolution map of DNA copy-number 
alterations. With the exception of regions on centromeres and telomeres, 
characterized by the presence of highly repetitive sequences, aCGH is available for the 




Figure 1. Principles of the aCGH technology. Whole genomic DNA from a control or reference 
(right) and genomic DNA from a test or patient (left) are differentially labeled with two 
different fluorescent dyes. The two genomic DNA samples are competitively cohybridized with 
large-insert clone DNA targets that have been robotically printed onto the microarray (middle). 
After hybridization of the DNA samples, the array is scanned to assess the relative fluorescence 
levels of each DNA for each target on the array. The ratio of fluorescent intensity between 
control and test DNA is used to identify copy number losses and gains on the chromosomes.5 
 
 
The first genomic arrays were based on bacterial artificial chromosome clones mapped 
during the initial phases of the Human Genome Project. These arrays essentially 
represented multiple fluorescence in situ hybridization assays performed 
simultaneously. The first arrays, consisting of hundreds of bacterial artificial 
chromosome clones, mostly limited to genomic regions of known medical significance, 
were “targeted” formats, containing collections of clones from specific genomic 
regions, designed to detect genomic imbalances associated with known genetic 
disorders.6,7 BAC probes are produced by insertions of DNA sequences to BAC (or PAC) 
clones in order to amplify the DNA sequences.8-10 The DNA is extracted, fragmented 
and spotted to glass slides at specific positions, where each DNA probe will represent 
100-200 kbp of the genome. Our group worked with a BAC array that contained 3528 
bacterial artificial chromosomes (BACs) spanning the genome. The particular BAC and 
PAC set was distributed to academic institutions by the Welcome Trust Sanger Institute 
(Cambridge, United Kingdom) and contains targets spaced at ~1 Mb density over a full 
genome, a set of subtelomeric sequences for each chromosome arm, and a few 
hundred probes selected for their involvement in oncogenesis. The clone content is 
available online in the ‘‘Cytoview’’ windows of the Sanger Institute mapping database 
site (available at: http://www.ensembl.org/ accessed August 2008). According to this 
database, clones were ordered along the chromosomes. Whole-genome arrays 
contained bacterial artificial chromosome clones from across the entire genome, 
which contained clones selected at regular intervals across the entire genome 
More recently alternative designs based on oligonucleotide probes have been 
developed. These high-density whole-genome arrays have a  resolution between 3 and 
35 kb. The design of an oligonucleotide aCGH is somewhat different from BAC arrays. 
Variations include manufacturing method, sample throughput capacity and probe 
length (25–80 bases). All available oligonucleotide platforms are whole genome arrays, 
but they can be customized either to function as targeted arrays (similar to available 
targeted BAC arrays) or to substantially increase resolution in a specific genomic region 





Published by Sanger and colleagues in 1977, the dideoxynucleotide method for DNA 
sequencing remained the standard for the next 30 years. The advent of DNA 
sequencing has significantly accelerated biological research and discovery and the high 
demand for low-cost sequencing has driven the development of new sequencing 
technologies. Next-generation sequencing (NGS, also known as massively parallel 
sequencing) technologies have a higher throughput than traditional sequencing 
methods. It allows millions of sequencing reactions to happen in parallel, using 
different approaches, either by creating micro-reactors and/or attaching DNA 
molecules to solid surfaces or beads.  Unlike previous methods, NGS generates millions 
of short reads (21-400 base pairs) and does not require amplification as sequencing 
could be performed from a single DNA molecule. The short reads can be quantified, 
allowing accurate copy number assessment. Moreover, with approaches that 
sequence both ends of a DNA molecule (paired end massively parallel sequencing), it 
has become possible to detect balanced and unbalanced somatic rearrangements (i.e. 
fusion genes) in a genome-wide fashion.  
Recently developed targeted sequence enrichment, coupled with NGS, represents a 
beneficial strategy for enhancing data generation to answer questions in Medicine. 
This marriage of technologies offers to the researchers a simple method to isolate and 
analyze a few to hundreds, or even thousands, of genes or genomic regions from few 
to many samples in a relatively efficient and effective manner. Sequence capture is 
fully scalable, making it useful for experiments requiring few genes or genomic regions, 
as well as those involving entire exomes.  
Targeted sequence enrichment refers to the suite of technologies designed to isolate a 
specific genomic fraction (e.g., genes, molecular markers, larger genomic regions) for 
subsequent NGS, ultimately resulting in an enriched pool of target sequences such that 
there is overall reduction in the genomic sequencing space, and hence greater 
sequence coverage for each targeted region. Several technologies exist for target 
enrichment, which can be classified by the mode of enrichment: (1) hybridization 
based sequence capture, (2) PCR-based amplification, and (3) molecular inversion 
probe-based amplification. The advantages of each of these have been discussed in 
depth.11 Many protocols and technological alternatives are available for hybridization-
based sequence capture. The two primary approaches involve hybridization of samples 
either to microarrays or to solution-based, pooled RNA-baits, both of which are 
complementary to the targeted genes. In both approaches, all targeted sequences are 
captured in one hybridization reaction.Since samples can be multiplexed using 
appropriate barcoding of NGS adapters, the potential to capture thousands of 
sequences simultaneously is proven. As with any technique,  key elements must be 
taken into consideration when designing  sequence capture experiments, including (1) 
the number of targets and the mean depth of coverage needed for each target, (2)  the 
probe specificity, (3) the biological system studied, (4) the  expected enrichment 
efficiency, and (5) the NGS technology  used.  
A final consideration in preparing for sequence capture is the type of NGS technology 
applied to the experiment. Four platforms for massively parallel DNA sequencing read 
production are used: the Roche/454 FLX12 
(http://www.454.com/enablingtechnology/the-system.asp), the Illumina/ Solexa 
Genome Analyzer (http://www.illumina.com/pages.ilmn?ID=203), the Applied 
Biosystems SOLiDTM System (http:// marketing.appliedbiosystems.com/images/ 
Product / Solid Knowledge / flash/ 102207/ solid.html) and the Ion Torrent system 
(http://www.iontorrent.com/ion-personal-genome-machine-sequencer/).  
The Roche/454 FLX Pyrosequencer was the first to achieve commercial introduction 
(2004) and uses an alternative sequencing technology known as pyrosequencing. In 
pyrosequencing, each incorporation of a nucleotide by DNA polymerase results in the 
release of pyrophosphate, which initiates a series of downstream reactions that 
ultimately produce light by the firefly enzyme luciferase. The amount of light produced 
is proportional to the number of nucleotides incorporated (up to the point of detector 























Figure 2. Work-flow of a NGS experiment with the 454-FLX technology.13  
 
 
Chronic lymphocytic leukemia 
 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western 
countries mainly affecting individuals older than 50 years. Clinical diagnosis of chronic 
lymphocytic leukemia is defined by absolute lymphocytosis of at least 5×10⁹/L, 
mature-appearing lymphocytes and an appropriate immunophenotype.14 These 
characteristics distinguish CLL from mantle-cell lymphoma, splenic marginal-zone 
lymphoma and other chronic lymphoproliferative disorders, the diseases that could 
mimic CLL.15  
CLL follows an extremely variable course, with survival ranging from months to 
decades. Recently, progress has been made in the identification of biological markers 
that could predict disease progression. Particularly, the expression of unmutated Ig 
genes, some cytogenetic abnormalities like 17p and 11q deletions and the expression 
of the zeta-associated protein 70 (ZAP-70) are associated to a poor prognosis. A major 
scientific goal is to find a biomolecular explanation for the CLL prognosis heterogeneity 
that can provide clues in the understanding of disease etiology and pathogenic 
mechanisms which promote the onset of the disease, as well as the progression and 
the evolution into more aggressive variants (Richter’s lymphoma or prolymphocytic 
leukemia).16  
 
Biology and pathophysiology 
CLL is characterized as an abnormal proliferation of malignant B lymphocytes.17 CLL 
was once thought to be a homogeneous disease, in which mature B cells accumulated 
largely due to a lack of normal cell death. Recently, however, CLL has been established 
as a heterogeneous disease of remarkable diversity. Differences in cell morphology, 
immunophenotype, cytogenetics, and molecular characteristics have been identified. 
This heterogeneity translates into varying clinical courses and responses to 
treatment.18  Table 1 provides a historical overview of some of the changes in how CLL 





Table 1. Comparison of historical and current views of CLL biology19 
 
Historical view Current view
CLL is a clinically heterogeneous disease with a 
homogeneous celllar origin
→
CLL is a clinically heterogeneous disease originating from B 
lymphocytes that may differ in activation, maturity or 
cellular subgroup
CLL is a disease derived from naive B lymphocytes →
CLL is a disease derived from antigen-experienced B 
lymphocytes that differ in the level of immunoglobulin 
variable gene mutations
Leukemic-cell accumulation occurs because of an inherent 
apoptotic defect involving the entire mass of leukemic 
→
Leukemic cell accumulation occurs because of survival 
signals from the external enviroment
CLL is a disease of lymphocyte accumulation →
CLL is a disease of lymphocyte accumulation with a higher 
associated level of proliferation than was previously 
recognized
Prognostic markers identify patients at various risk levels 
(low, intermediate or high in the Rai staging categories, 
and A, B or C in the Binet categories) with an 
acknowledged heterogeneity in clinical outcomes among 
patients in the low- and intermediate-risk categories
→
New molecular biomarkers are used in both diagnosis and 





Malignant lymphocytes characteristically appear small and mature, although large 
atypical cells, cleaved cells, or prolymphocytic cells could also be observed.20 In CLL, 
malignant, long-lived lymphocytes accumulate in the blood, bone marrow, spleen, and 
lymph nodes. The phenotype of CLL distinguishes it from other B-cell malignancies by 
the presence of B-cell markers (CD19, CD20, CD23, and CD43) along with CD5, an 
antigen normally found on T cells. Typically, CLL cells also express surface 
immunoglobulin (slg), CD79b, CD20, and CD22 at low density. The phenotypic features 
of CLL are not only used for initial diagnosis, but they also play a role in the assessment 
of minimal residual disease (MRD), an important prognostic parameter defined as <1 
clonal B-cell in 10,000 leukocytes.20 
 
Prognostic markers 
The Rai and Binet staging systems are simple and reliable prognostic tools that are in 
the basis of the decision to treat most patients.21,22 However, there is considerable 
variation in outcome with each stage. Therefore, additional factors are more 
commonly being considered in predicting individual patient prognosis and stratifying 
patient risks. 
A quick review of the literature identifies over 35 different prognostic markers. Some 
of these are classified as “classical”, whereas others are classified as “biological” (Table 
1). The classical prognostic markers tend to be those obtainable from routine history, 
physical examination, and lab work. The biological prognostic factors tend to assess 
molecular aspects of the CLL cell themselves. 
 
Table 2. Chronic lymphocytic leukemia: classical and biological prognostic markers. 
 
 
Classical prognostic markers 
 
    Clinical stage 
    Blood lymphocyte count 
    Lymphocytes morphology in peripheral blood 
    Blood lymphocyte doubling time 
    Bone marrow infiltration degree (aspirate/biopsy) 
Biological prognostic markers 
Extensively studied 
 
    Serum markers 
    IGVH mutational status 
    V3-21 gene usage 
    Cytogenetics 
    CD38 expression 
    ZAP-70 expression 
Requiring further studies 
 
    Chromosomal translocations 
    CLLU1 expression 
    microRNA signature 
    TCL-1 gene 
    Bcl2/Bax ratio 
    MDR1/MDR3 genes 
    Activation-induce cytidine deaminase (AID) mRNA 
    Lipoprotein lipase A expression 
    ADAM29 expression 
    VEGF 
    Thrombopoietin 
    Telomere lenght and telomerase activity 
    CD49d 
    CD69 
    FCRL 
Treatment related 
 




Genomic abnormalities in CLL 
Our knowledge of genomic aberrations in CLL has initially been based on chromosome 
banding studies using TPA as a mitogen.23 These studies have been held back by the 
low mitotic activity of CLL cells. With this method, clonal chromosomal aberrations 
were detected in only 40 to 50% of cases, the most common being trisomy 12 and 
abnormalities of chromosome band 13q14.23 More recently, metaphase analysis has 
had a “revival” because the metaphase yield has been improved by stimulation of CLL 
cells with alternative methods like CD40 ligand expressing cells and IL-4 or the addition 
to the cultures of CpG-oligodeoxynucleotides and IL-2.24 This approach revealed that 
translocations are present in about one third of CLL patients. After stimulation with 
CpG-oligodeoxynucleotides and IL-2, the observed aberration rate was comparable to 
the rate detected by parallel interphase FISH, and the method frequently detected 
balanced and unbalanced translocations.25 These studies also demonstrated that 
additional cases of complex aberrations (more than 3 aberrations) can be detected. In 
a recent update on the results of metaphase cytogenetics after stimulation with CpG-
oligonucleotide DSP30 and IL-2, a total of 500/506 (98.8%) cases were successfully 
analyzed.26 Aberrations were detected in 415 of 500 (83.0%) cases by banding and only 
in 392 of 500 (78.4%) cases by FISH due to limitations of the probe set. Future studies 
will show if the metaphase cytogenetics after stimulation will result in a deeper 
understanding of the disease and prognostic subgroups.27  
Fluorescence in-situ hybridization (FISH) allows the detection of chromosomal 
aberrations irrespective of the cell's ability to divide. 28 Genomic aberrations can be 
identified in about 80% of CLL cases by FISH with a disease specific probe set. The most 
common recurrent chromosomal abnormalities include trisomy 12 as well as deletions 
of 13q 11q, 17p and 6q.29 A subdivision based on these aberrations is important, as it is 
associated with the rate of disease progression and the overall survival time of CLL. 
Five prognostic categories have been defined in a hierarchical model showing a shorter 
survival in patients with 17p deletion and 11q deletion (median survival of 32 and 79 
months, respectively), while the survival is longer for patients with trisomy 12q normal 
karyotype, and deletion 13q as the sole abnormality (114, 111, and 133 months, 
respectively).29 FISH is  the current method of choice in clinical setting. However, FISH 
only “cover” a limited set of aberrations and the recent developments of comparative 
genome hybridization (CGH) and in particular high resolution SNP arrays have lead to a 
better understanding of the genetic profile of CLL. 
 
 
IGVH mutational status 
More than a decade ago the simultaneous publication of two papers seemed to 
explain the heterogeneity that clinicians had observed in the natural history of chronic 
lymphocytic leukemia (CLL). 30,31  Both studies mutually corroborated the finding that 
IGVH mutational status identifies two subsets of CLL, one with a median survival of 8 
years and the other with a median survival of 25 years. Somatic mutations of the VH 
gene region of the heavy chain of immunoglobulins are present in about half of all CLL 
cases. Unmutated cases originate from cells in the pregerminal center and clearly are 
associated with a worse prognosis than mutated CLL cells arising from the 
postgerminal center. The definition of non-mutated vs mutated pattern resides in a 
cutoff point, defined arbitrarily as a homology greater than 98% (non-mutated) gene 
most similar to the germline.32 Patients with CLL and an unmutated status have an 
unfavorable course and progress more rapidly, as opposed to patients exhibiting a 
mutated state, whose survival is much longer. Unmutated CLL patients have a greater 
tendency to acquire poor prognostic cytogenetic abnormalities. IGVH mutational 
status and cytogenetic abnormalities identified by FISH have a major impact on the 
survival of patients with CLL, but while cytogenetic changes during the course of the 




Gene expression profiling  
The value of gene expression profiling (GEP) in the study of CLL is widely accepted. 
Such studies have identified new prognosis markers such as ZAP-70, LPL, PEG10 and 
CLLU1. Some of these are already well-established factors used in clinical practice, 
while the application of others is under study.   
Despite clinical and molecular differences, global gene expression profile analysis 
demonstrated that all CLL show a homogeneous gene expression profile irrespective of 
their IgV mutational status and differing from other lymphoid cancers, which suggests 
a common cellular precursor.33,34 These analyses revealed that the gene expression 
profile of all CLL is related to that of antigen-experienced B cells, which in the human 
are defined by expression of the CD27 cell surface antigen, and that include classical 
memory B cells and marginal zone B cells which can be somatically mutated or 
unmutated.35,36 However, despite sharing a common signature, CLLs with mutated 
IGVH  displayed a different expression of more than 100 genes. Among these, over-
expression of genes encoding zeta-chain-associated protein 70 (ZAP-70), lipoprotein 
lipase (LPL), BCL-7A, dystrophin and gravin were observed in the unmutated cases, 
while the mutated cases over-express Wnt3, CTLA-4, NRIP1 nuclear receptor gene, 
ADAM29 and the transcription factor TCF7.37 These results suggested that indolent 
mutated and aggressive unmutated CLLs constitute two variants of the same disease. 
The reasons accounting for these striking differences in clinical outcomes of these two 
variants remain unsolved. ZAP-70 appeared to be one of the most significant.34 
Subsequently, the correlation of ZAP-70 expression with the mutational status of the 
IGVH genes was assessed in larger series of CLL patients, where ZAP-70 was mostly 
found expressed in unmutated CLL.38 Further clinical studies revealed that ZAP-70 was 
also an independent prognostic marker.39 In addition, genes that are significantly more 
highly expressed are located in the corresponding aberrant chromosomal regions, 
indicating the existence of a genetic dosage effect, which may have a pathogenic role 
in CLL. Surprisingly, significant differences in gene expression according to sex were 
also found, which suggests that differences in molecular signatures relating to IGVH 
mutational status may be related to the sex of the patient.40  
 
 
Kinetics of CLL 
CLL had been considered as a disease of failed apoptosis and passive accumulation. 
This view is supported by the observation that the great majority (~98%) of peripheral 
circulating CLL cells are arrested in G0 or the early G1 phase and have overexpression 
of antiapoptotic proteins, such as BCL2. CLL B-cells are characterized by high 
expression of BCL-2 protein in the absence of specific translocations and by high 
expression of the p27kip protein, which blocks the progression into cell cycle. Given 
the key role of this protein in the cell cycle progression, the over-expression in CLL cells 
could account for the accumulation of B cells in early phases of the cell cycle. In 
addition, other members of the BCL-2 family such as anti-apoptotic proteins BCL-XL, 
BAG-1 and MCL-1 are overexpressed, while pro-apoptotic proteins like BAX and BCL-XS 
are under-expressed.41,42   
The birth-rate of the leukemic cell clone was considered to be low and without 
influence on the disease. However, this view of CLL has been recently revised. Thus in 
vivo studies showed that there is a small but variable fraction of the monoclonal CLL 
cells that actually proliferate, and a fraction of cells that undergo apoptosis.43 The 
same study showed that patients with accumulation of B cells showed a higher birth 
rate and a lower death rate of cells. In comparison, patients with stable B cell numbers 
displayed equilibrium between proliferation and apoptosis.  
As opposed to in vivo results, apoptosis occurs after in vitro culture, which suggests a 
role of the microenvironment in CLL cell survival.44 Therefore the host 
microenvironment of B cells determines the balance between resistance to apoptosis 
and active proliferation by providing different sets of signals and conditions. CLL B-cells 
communicate with cells in the microenvironment, such as T cells and stromal cells, and 
the interaction with these cells provide essential signals for survival and expansion of 
the CLL cells promoted by molecules such as IL-4 and CD40 ligation, whose effect also 




MicroRNAs (miRNAs or miRs) are noncoding RNAs that have the capacity for 
simultaneous regulation of tens to hundreds of genes through direct targeting of 
untranslated regions (UTR)47-49 . MiRNAs represent the best characterized member of a 
family of noncoding RNAs, many of which are currently being studied. MiRNA targeting 
results in either degradation of mRNA or inhibition of translation. In silico models 
suggest that miRNAs may be responsible for the regulation of more than 30% of the 
genome.47 MiRNAs are important for biological processes, including proliferation, 
apoptosis, development, and cellular differentiation50 and have the capacity to 
function as either oncogenes or tumor suppressors.47 Deregulation in expression of 
miRNAs in some malignancies compared to normal tissue as well as their frequent 
location in fragile chromosomal regions supports their relevance to the development 
of malignancies.51 
The first description of a miRNA associated to cancer was reported in CLL.52 Calin et al 
showed that miR-15a/16-1 were located in 13q14.3 and were either deleted or 
downregulated in 68% of patients with CLL. Further studies found that these miRNAs 
have as target the mRNA encoding the antiapoptotic protein B-cell CLL/lymphoma 2 
(BCL2), the upregulation of which is critical for CLL cell survival.53  Importantly, the 
direct interaction of miR-15/miR-16 with BCL2 transcripts delayed protein translation, 
induced apoptosis, and reinforced the role of miRNAs as part of a new class of tumor 
suppressor genes.  
Given the apparent link between cytogenetic abnormalities in CLL and miRNA 
deregulation, miRNAs have become attractive candidates as both biomarkers and 
therapeutic targets for CLL. The interaction between miRNAs, target genes, and 





Figure 3. miRNAs implicated in apoptotic, survival, and proliferative pathways in CLL. 
Arrowheads represent expression patterns in CLL. Genes in parentheses represent validated 
targets for select miRNAs.54  
 
 
Recently a miRNA analysis in a cohort of 61 treatment-naive CLL patients has been 
performed. The cohort represented several distinct karyotypes and the authors 
identified miRNAs that distinguished all karyotype groups, showing that miR-181a 
expression correlated with a shortened time to treatment as well as distinguished 
aggressive from indolent disease in 17p deletion cases55. Calin et al conducted miRNA 
expression profiling on a well-annotated series of 94 CLL patients and identified a 
panel of 13 genes that correlated with ZAP-70 expression and IGVH mutational 
status.56 In addition, a subgroup of nine miRNAs (181b, 155, 146, 24-2, 23b, 23a, 222, 
221, and 29c) differentiated patients with a short interval to therapy from patients 
with a longer interval to therapy.  The miR-34 family has been also implicated in CLL. 
Thus miR-34a expression partially correlated with p53 status and patients with p53 
mutations or 17p- in general had lower miR-34a expression. However, the link 
between p53 mutational/deletional status and miR-34a has proven to be much more 
complex and further studies are required.  
The TCL1 gene, located at 14q32.1, is overexpressed in 25-35% of CLL cases.57 TCL1 
overexpression is increased in CLL patients with unmutated IGVH and elevated ZAP-70, 
suggesting its role in aggressive forms of CLL. TCL1 transgenic animals represent the 
best current animal model for the development of CLL.58 Through the use of the TCL1A 
murine model, investigators have identified other miRNAs relevant to the 
pathogenesis of CLL such as miR-29 and miR-181.59  
The rapid advancement of miRNA research in just the past few years suggests that the 
roles of many other miRNAs in CLL have yet to be discovered. Thus miRNAs remain one 
of the most exciting new avenues for CLL research.  
 
 
Heat shock proteins in CLL 
Over the last decade, research has implicated a group of molecular chaperones termed 
Heat Shock Proteins (HSPs) as major contributors to cancer progression and the 
development of chemo-resistance. In tumor cells, including CLL cells, HSPs are 
upregulated and may contribute to prolonged tumor cell survival via several 
mechanisms that remain to be fully revealed.60-62 
Hsp90 is a molecular chaperone that catalyses the conformational maturation of a 
large number of signaling proteins in cancer that are collectively described as ‘clients’. 
In advanced tumors, Hsp90 exists in an activated form complexed with other 
molecular chaperones, whereas in normal tissue Hsp90 is present in a latent, 
uncomplexed state.63 Research into the involvement of HSP90 in cancer progression 
has identified a wide variety of client proteins that may contribute to the progression 
of both solid tumors and hematological malignancies.  
It has been demonstrated that ZAP-70 in CLL cells co-immunoprecipitates with HSP90, 
while ZAP-70 from normal T-cells does not. In addition, treatment of ZAP-70+ CLL cells 
with HSP90 inhibitors resulted in degradation of ZAP-70, while treatment of T-cells 
from CLL and control patients with HSP90 inhibitors did not affect the expression of 
ZAP-70. Manipulation of ZAP-70- CLL cells to express ZAP-70 was shown to activate 
HSP90 and induce sensitivity to 17-AAG, an HSP90 inhibitor.64  
HSP90 chaperones, a broad array of protein kinases involved in signal transduction 
pathways, including phosphorylated Akt, Lyn, B-Raf and IκK.61,62,65 The interaction of 
HSP90 with these phosphorylated kinases prevents dephosphorylation of the kinase 
and its subsequent inactivation, therefore maintaining its activity. The over-activity of 
Akt,66 Lyn67 and implied elevation of IκK68 in CLL cells has been previously observed and 
thought to contribute to cell survival and activation of downstream kinases. IkK over-
activity has implications for a large number of NF-κB target genes including Bcl-2, X-
IAP, c-FLIP and Mcl-1.68 In fact, a number of these proteins have been implicated in the 
progression of CLL and have been found to correlate with poor prognosis which may 
suggest a clear link to over-activity of NF-κB69,70. Interestingly, Activation-Induced 
Cytidine Deaminase (AID), which has been shown to have prognostic significance in 
CLL,71,72 is an HSP90 client and chemical inhibition of HSP90 activity results in 
destabilisation and proteosomal degradation of AID and reduced antibody 
diversification.73 Furthermore, HSP90 inhibitor-induced cell death appears to be p53 
independent suggesting that it may also be useful in the treatment of patients with a 
mutated p53 status.  
It would appear that HSP90 inhibitor treatment of CLL cells targets a wide variety of 
proteins, many of which have been implicated in the progression of the disease. Thus, 
targeting HSPs is an attractive strategy in CLL.  
 
 
Next generation sequencing studies in CLL 
Whole genome sequencing of cases with CLL led to the discovery of several genes, 
previously unsuspected to be involved in this disease.  Application of next generation 
sequencing technology has identified previously unknown recurrent mutations in 
NOTCH1, XPO1, MYD88, and KLHL6 in 12.2%, 2.9%, 2.4%, and 1.8% of CLL cases, 
respectively.74 NOTCH1 and XPO1 mutations are associated with IGVH unmutated CLL 
while MYD88 and KHL6 are associated with IGVH mutated CLL. Both NOTCH1 and 
MYD88 mutations appear to be activating mutations. NOTCH1 mutated cases have 
been shown to overexpress NOTCH1 pathway genes and are associated with 
unfavorable prognosis. Thus, in addition to a potential therapeutic target, this 
mutation appears to confer prognostic information.  Further studies on the coding 
genome of CLL have also revealed a recurrent mutation in a component of the 
spliceosome, SF3B1.75,76 These somatic mutations were missense mutations that are 
clustered in hotspot codons 662, 666 and 700 and predicted poor prognosis. The 
mutations were found in 9.8% of CLL at diagnosis75 and in 17% of fludarabine 
refractory cases.76 This gene has also been shown to be mutated in myelodysplastic 
syndromes (refractory anemia with ring sideroblasts).77 Therefore NGS appears to be a 
highly effective technique in identifying new genetic lesions and future studies are 














The general aim of this thesis was to gain insight into the pathophysiological 
mechanisms of CLL in the different cytogenetic subgroups by applying a combined 
analysis of the genome and transcriptome of B clonal lymphocytes.  
 
More specifically the aims were as follows: 
 
- To screen and to identify new recurrent aberrations in a cohort of newly 
diagnosed CLL patients by genomic microarrays (aCGH). 
- To analyze, by applying two microarray platforms, the gene expression profile 
of the cytogenetic CLL subgroups: normal FISH, 13q-, +12, 11q- and 17q-, as 
well as the new recurrent abnormalities identified by aCGH studies. 
- To characterize the CLL patients with 13q deletion by gene expression profile 
and microRNA studies. 
- To identify new variations in genes involved in CLL pathogenesis by applying 
next-generation sequencing techniques. 
- To define the functional implication of the genes with altered expression 


































Paper I – Array-based genomic profiling in CLL 
The advancement of genomics technologies has offered a range of experimental 
approaches to study the molecular variation underlying the biological and clinical 
heterogeneity of CLL. Microarray-based methodology provides genomic information of 
the whole genome in a single experiment. Thus both CGHarrays and expression arrays 
give a full scope of the cancer genome. Several CLL studies have applied microarrays 
for the detection of copy number abnormalities (CNAs), and have 
served/supplied/added/produced  additional information on genome-wide alterations 
in this disease.78-84 Furthermore expression microarrays have contributed to the 
molecular characterization of CLL.33,34,40,85,86 
Our aim was to investigate genomic aberrations in CLL by a global analysis of the 
genome and the transcriptome and to study the copy number variations in CLL 




Figure 4. Outline for the genomic characterization of CLL 
 
We have applied high density aCGH screening in 67 CLL samples. Our customized 1Mb-
BAC array contained 3,523 clones, kindly provided by the Sanger Institute, Cambridge 
(UK), spanning the genome. The data analysis was carried out with GenePixPro 4.0. To 
study the gains and losses a binary segmentation method was applied. In a selected 
group of patients, the results were confirmed by oligonucleotide arrays (NimbleGen) 
and FISH. The recurrent alterations were confirmed by FISH. Gene expression profile 
was analyzed by HU-133 Plus 2.0 array (Affymetrix). In all cases clinical data, FISH, IGH 
somatic mutations and immunophenotype were also available. 
A total of 75% of patients displayed cytogenetic aberrations: 443 altered chromosomal 
regions were found, of which 237 (53%) were deletions. The median number of 
changes per patient was five (range 0–14). Overall array CGH results correlated with 
FISH analysis (+12, 11q- and 17p- cases), although the correlation was only 48% in 13q- 
subgroup. Besides the alterations reported by FISH (11q-, +12, 11q-, and 17p-), 
genomic arrays detected other recurrent changes: losses in 11q13.3 (16%), in 5q13.3–
q14.1, 5q31.1 and 7q22 (6% each), as well as gains in 1q21.3–q22 (22%), 11q13.3 
(21%), 16q23.2–q24.2 (21%), 6p21.31–p21.1 (19%) and 10q22.3 (7.5%). These 
aberrations can also be observed in patients with normal FISH. Thus our data confirms 
the heterogeneity of CLL.  
We also defined a new recurrent gain in 20q in 19% (13/67) of the CLL patients. 
Genomic analysis identified the minimum region of gain on 20q13.12 of ~2.31 MB 
involving three clones at linear positions (42 188 467–44 495 323). To better 
characterize the 20q13.12 gain, FISH analysis was also carried out in a validation series 
of 58 patients and 17% patients showed this alteration in ≥4.5% cells (ranging from 
4,5% to 12%). This gain was associated (P=0.002) with a high frequency of 
chromosomal changes as revealed by aCGH and overexpression of the genes located in 
this region.  
Oligonucleotide expression microarrays correlated with the regions of loss or gain of 
genomic material, suggesting that the changes in gene expression are related to 
alterations in copy number, which confirms the gene dosage effect previously 
described in CLL.  
 
 
Papers II and III – Characterization of CLL patients with a high number of 
13q- cells. 
 
Patients with loss on 13q show the better outcome in CLL. However, in some series 
with a long-term follow-up, patients with CLL and a normal karyotype showed a longer 
survival from 12 years on, as compared to patients with 13q-,30 suggesting that 13q- 
subgroup could be heterogeneous. In addition, several studies have demonstrated that 
the percentage of cells displaying a particular cytogenetic abnormality (e.g. loss of 
P53)87 or antigenic markers (e.g. CD38 or ZAP-70)88 can be related to prognosis. For 
these reasons, an analysis of patients diagnosed with CLL and deletion in 13q14, as the 
sole cytogenetic abnormality, was carried out. The clinical features, including outcome, 
and the biological features of the patients displaying different degrees of infiltration by 
13q- cells, were also assessed.  
The study population performed in Paper II comprised 350 non-selected patients, from 
nine Spanish institutions, diagnosed as CLL. Clinical data were recorded by reviewing 
the clinical histories of patients included in the study. In most cases (283 patients; 
81%) the FISH study was performed at the time of diagnosis. Progression was defined 
according to previously reported criteria: the presence of disease-related symptoms, 
massive or progressive organomegaly, bone marrow failure or recurrent infections89. 
At the time of diagnosis 109 patients showed 13q deletion as the sole FISH abnormality 
and the study was focused on this group of patients. A significantly longer survival was 
observed in the cohort of patients with losses in 13q in less than 80% of cells. Thus, in 
the subgroup of patients with 80% or more of cells with loss of 13q the overall survival 
was 56 months (95% CI: 39-73 months), while in the group of patients in whom less 
than 80% of cells showed losses in 13q, the overall survival had not been reached (95% 
CI: 163-254 months) (P<0.0001). A significantly shorter time to first therapy (TFT) was 
observed in the cohort of patients with 80% or more of cells showing losses in 13q 
(median of 38 months; 95% CI: 21-55 months) as compared to those cases with less 
than 80% of 13q- (median of 87 months; 95% CI: 21-153 months) (P=0.05). Thus, the 
percentage of cells displaying 13q deletion influences the outcome of CLL patients. 
These results have been corroborated by two independents studies.90,91 However, to 
the best of our knowledge, the molecular characteristics of 13q- CLL patients have not 
been so far analyzed in detail in order to better understand why these patients could 
have a different outcome.  Thus, as a next step toward the elucidation of biological 
differences within 13q- subgroup, a gene expression profile studies using two 
microarray platforms from Affymetrix: HG U133 Plus 2.0 and Human Exon 1.0 ST was 
carried out. 
For the gene expression profile analysis two groups of patients with 13q- were 
compared: those in whom 80% or more of cells showed 13q- (13q-H CLL) and those in 
whom less than 80% of cells showed 13q losses (13q-L CLL). The gene function analysis 
performed in Paper II revealed that most of these genes were involved in apoptosis, 
cellular growth and proliferation, mitochondrial, endoplasmic reticulum (ER) and 
calcium mediated activity. In Paper III, the gene expression analysis was performed 
using the Affymetrix Human Exon arrays 1.0, which offer a more fine-grained view of 
gene expression than the former generation of chips. Thus, the data obtained provided 
great insights into the biological mechanisms underlying the clinical differences 
observed in this CLL subgroup. Overall, the correlation between both platforms was 
excellent. In Paper III we also performed a validation analysis on CD19+ 
immunomagnetically purified cells from an independent cohort of patients. The 




Figure 5. Overview of the experimental strategy followed in Paper III. 
 
The transcriptome of 97 CLL patients and 5 healthy controls was analyzed. We split the 
samples in two cohorts: (1) Initial Cohort (n=65): PBMC cells, isolated from peripheral 
blood using Ficoll gradient and (2) Validation Cohort: CD19+ cells from 32 CLL patients 
and 5 healthy controls, immunomagnetically purified. The Initial Cohort was a subset 
of a group of CLL patients previously studied by our group by using genomic 
microarrays (Rodríguez et al, Ann Oncol 2012). Differentially expressed genes were 
identified using the SAM test in a supervised approach. To test whether the resulting 
lists of candidate genes were significantly associated with the CLL subgroups, a Global 
Test algorithm was used. In addition, in the Validation Cohort, we performed an 
unsupervised clustering analysis (Principal Component Analysis) to explore and 
represent the differences between the 13q- categories and controls. (3) The panels of 
differentially expressed genes were further functionally analyzed. An integrative 
analysis of the miRNA and gene expression profile was also performed (Supplementary 
Figure 2 in Paper III). (4) Gene expression changes for selected genes and miRNAs were 
tested using semi-quantitative SYBRgreen PCR and Taqman microRNA assays, 
respectively. 
A total of 3,450 genes significantly distinguished 13q-H from 13q-L patients. These 
comprised 1,244 overexpressed genes and 2,206 underexpressed in the 13q-H group, 
defining the 13q-H signature. To assess the biological significance of the deregulated 
genes, a further analysis of the 3,450 deregulated genes characterizing the 13q-H CLL 
was carried out, revealing in this group of patients the involvement of several 
pathways, primarily related to cell proliferation, apoptosis and cell signaling. 
Moreover, 13q-H CLL patients were also characterized by a striking overrepresentation 
of deregulated miRNAs. A total of 15 miRNAs were deregulated in 13q-H relative to 
13q-L patients. Hsa-miR-155 was the most highly upregulated miRNA (Rfold=3.70), 
while hsa-miR-223 was the most significantly downregulated (Rfold=0.10). The post-
transcriptional regulatory network of miRNA and genes in CLL patients with more than 
80% of 13q- cells was carried out by analyzing the miRNA-mRNA relationships and the 
pathway analysis demonstrated that B cell receptor signaling, PI3K signaling and NFkB 
signaling were among the most strongly affected pathways in 13q-H patients, 
highlighting the importance of miRNA regulation in CLL. We also analyzed the gene 
signature of CLL high risk cytogenetic subgroups in comparison with 13q- patients. 
Surprisingly, our results suggest that some of the biological characteristics of 13q-H CLL 
patients were similar to those of high-risk cytogenetic subgroups, since they share the 
deregulation of several key signaling pathways. By contrast, 13q-L patients had similar 
gene expression to that of CLL with normal FISH.  
Therefore, both clinical and biological studies demonstrate that CLL patients with 13q- 
















Paper IV – Mutational study of CLL by targeted resequencing. 
The use of next generation sequencing (NGS) techniques has taken genomic research 
into a new era. The application of this technology has provided a better knowledge of 
the genetic complexity and heterogeneity of CLL. Technological innovation in DNA 
sequencing offers the promise of a more comprehensive, cost-effective and systematic 
ascertainment of genetic variation. A major bottleneck, however, is in isolating the 
target DNA to be sequenced. Based in literature and our previous results from GEP 
studies, we have applied targeted genome capture by using a NimbleGen array and a 
high-throughput FLX-454 sequencing to the genomic DNA of four CLL patients. By this 
targeted array-based sequence enrichment we have isolated the sequences of 93 
selected genes (Supplementary Table S1) and two entire regions: 13q14.3 (50043128-
50382849 bp) and 17p13.1 (7500000-7535000 bp).  













Figure 6. Targeted genome capture & next-generation sequencing  
Briefly, genomic DNA was sonicated or nebulized to small fragment size (500bp). The 
fragment pool was denatured and hybridized to a NimbleGen Sequence Capture array 
designed to target the genomic regions of interest. Following hybridization, any 
unbound fraction was removed by washing and the enriched fragment pool was eluted 
and recovered from the array. The enriched fragment pool was amplified by ligation-
mediated PCR. The end product was an enriched, amplified, target DNA pool ready for 
high-throughput sequencing. The software determines the sequence of more than 
1,000,000 individual reads per 10-hour instrument run. The sequencing-data analysis 
consist of align the reads and map them to the reference genome. Basic raw data 
analysis was carried out using the GS Run Browser and GS Reference Mapper software 
version 2.0.01 (Roche Applied Science). Each sequence read was compared with the 
entire appropriate version of the human genome. Captured sequences mapped 
uniquely back to regions within the target regions were considered sequencing hits. 
We used a custom-made data analysis pipeline to annotate detected variants with 
various kinds of information, including known single-nucleotide polymorphisms (SNPs), 
amino acid consequences, genomic location and miRNA binding sites. To validate the 
variants identified Sanger sequencing was performed. A total of 4 patients with CLL and 




Figure 6. Number of variants identified in CLL and control samples. 
 
The enrichment assay followed by NGS allowed the detection of over 1 600 
variations/sample (median 1 721, range 1 618-1 823) (Figure 6). All putative variants 
were first compared with published single nucleotide polymorphism (SNP) data (dbSNP 
build 130; http://www.ncbi.nlm.nih.gov/projects/SNP). Most of the variants detected 
were identified as known SNPs and 226 variants were present in all the patients. Thus, 
altogether they were discarded. Overall, 10% of variants detected in each sample were 
variations not previously described. 73 were missense variations affecting 33 genes 
were detected. Most of the genes had one (70%) or two (12%) variations. Results are 
summarized in Table 3.  
 
n % Gene Symbol
1 23 70
ABCB6, ADAMTS1, ALAS2, BCL6, CAPRIN2, CDK6, CYP4F3, DICER1, 
DLEU7, FECH, GART, HSPD1, MLF1, MLL3, MRLPL27, MRLPL35, 
MRLPL37, MTFR1, PCCB, PIK3CA, RAPGEF2, SLC25A37, SOD1
2 4 12 ACAT1, CHFR,  PHLPP2, TIMM50
3 1 3 FLT3
4 3 9 ATM, GCAT, GDF15
6 1 3 TET2




Table 3. Variations detected in the targeted resequencing experiment. 
 
Interestingly, a 4bp insertion/deletion polymorphism (rs2307842) in the 3´UTR of 
HSP90B1, target site for miR-223 was detected (Figure 7). We hypothesized that this 
‘GACT’ deletion disrupts the binding site for miR-223 thereby increasing the translation 
of HSP90B1. Both HSP90 and miR-223 have been previously implicated in CLL, thus we 
decided to gain insight in this field. 
First we confirmed that miR-223 regulates HSP90B1 expression by 3´UTR reporter 
assays. The rationale for using this assay is that the binding of a given miRNA to its 
specific mRNA target site will repress reporter protein production (luciferase) thereby 
reducing activity/expression that can be measured and compared to a control (renilla). 
The experimental approach is to clone the 3´UTR of the target gene of interest 
immediately downstream of the luciferase open reading frame sequence contained in 
the reporter plasmid. The recombinant plasmid and the miRNA of interest are then 




Figure 7.  HSP90B1 3´UTR wild type and mutated.  
The wild-type (WT) and mutated (MUT) 3´UTR of HSP90B1, with the seed region (bold) and 
base deletion (bold and underlined) were sub-cloned into luciferase reporter and are shown.  
 
The double-stranded oligonucleotides corresponding to the wild-type (WT-3’UTR) or 
mutant (MUT-3’UTR) miR-223 binding site in the UTR of HSP90B1 were synthesized 
and pmirGLO Vectors made up of an SV40 promoter, the Renilla-luciferase gene, and 
the 3´UTR of HSP90B1 were transfected into HEK293 cells. This assay confirmed the 
influence of the rs2307842 on HSP90B1 transcript stability, as the mutant reporters 
had more luciferase activity than their respective wild-type ones, which means that the 





Figure 8. Luciferase reporter assays to confirm targeting of HSP90B1 3´UTR by miR-223. 
Ectopic miR-223 expression inhibits wild-type but not mutant HSP90B1 3´UTR reporter activity 
in HEK293 cells. Cells were co-transfected with miR-223 precursor/negative control (NC) 
miRNA and with either WT or MUT HSP90B1 3´UTR reporter construct. Luciferase activity assay 
was performed at 24h after transfection. The columns represent normalized relative luciferase 
activity (RLU) by means with 95% confidence intervals from 4 independent experiments 
(Mann-Whitney test, *P<0.05). 
We also validate this finding by transfecting two cell lines with synthetic miR-223 and 
measuring HSP90B1 expression by semi-quantitative PCR and Western blot. The cell 
lines were MM1S (mutant 3´UTR) and H929 (wild-type 3´UTR). All the experiments 
were done in triplicate and both semi-quantitative PCR and western blot analyses of 
HSP90B1 mRNA and protein showed that the rs2307842 determines an increased 
expression of the miR-223 target. 
 
To evaluate the clinical impact of HSP90B1 3´UTR polymorphism, we expanded the 
study to 109 additional patients with CLL and 32 healthy controls. Sequencing of the 
HSP90B1 3´UTR region was performed by pyrosequencing (PyroMark Q24 system, 
Qiagen). rs2307842 was detected in 27/109 (25%) patients and 8/32 (25%) healthy 
controls, as expected. Overall, we did not find any significant relationship between 
rs2307842 and clinical characteristics of CLL patients. We also analyzed HSP90B1 
expression in a series of 21 CLL patients (15 WT and 6 mutant) by semi-quantitative 
PCR and we observed a statistically significant HSP90B1 overexpression (P=0.039) in 





Figure 9. . Gene expression levels of HSP90B1 in CLL patients assessed by semi-quantitative 
PCR analysis. Box plots show the relative upregulation of HSP90B1 in CLL patients with 
rs2307842 (MUT) compared with wild type-CLL patients (WT). The thick line inside the box plot 
indicates the median expression levels and the box shows the 25th and 75th percentiles, while 
the whiskers show the maximum and minimum values. Outliers (extreme values falling out of 
the main distribution) are represented by open circles. Statistical significance was determined 
using the Mann-Whitney U test (P<0.05).  
 
Thus, we demonstrate that, in CLL patients, the presence of rs2307842 in HSP90B1 
3´UTR region leads to HSP90B1 overexpression due to the disruption of the miR-223 
binding site.  
Downregulation of miR-223 has been recently reported to have prognostic significance 
in CLL.92 However, there is no evidence of the pathogenetic mechanism of this miRNA 
in CLL patients, and no target has been proposed or validated for miR-223 in CLL until 
date. Thus, this work provides novel information about how the downregulation of 
miR-223 can be determining the poor outcome of CLL patients, maybe through 
upregulation of HSP90B1 expression. These results could point out HSP90B1 as a new 
pathogenic mechanism in CLL, given its role in apoptosis resistance and cell survival 
promotion in several types of cancer. Moreover, HSP90 chaperones a number of 
important proteins with a key role in CLL such as ZAP-70, Akt and AID. HSP90 has been 
also involved in BCL-2 regulation and apoptosis resistance in CLL. Thus, our results 
could be a first step towards elucidation of HSP90 role in CLL and further investigations 
















CLL has been established as a heterogeneous disease of remarkable diversity. No single 
genetic mutation or abnormality responsible for CLL development has been identified. 
The disease is characterized by a variety of chromosomal abnormalities, which have 
been shown to be important predictors of disease outcome. Considering the molecular 
heterogeneity of CLL, genome-wide studies and analysis of global pathways are 
powerful tools for the analysis of genetic alterations in CLL, rather than the study of 
single targets.  
Comparative genomic hybridization arrays are reliable tools to investigate the genetic 
abnormalities in CLL with a higher resolution, compared with FISH and conventional 
cytogenetics. Several studies have demonstrated the presence of new, cytogenetically 
cryptic and recurrent chromosomal changes, such as gain of 2p and deletions of 8p, 
18q and 22q.  Our study identified a previously undescribed recurrent region of gain in 
CLL, located on 20q13 in 19% of CLL patients. This frequency is similar to other well 
characterized abnormalities in CLL (+12, 11q-, and 17p-).  Gains in 20q13 in CLL did not 
occur as a single aberration, because all CLL patients with gains in this region also 
displayed additional genetic changes. In fact, gains on 20q were associated with 
genomic complexity. It is of note that genomic complexity has a significant impact on 
cancer prognosis and a number of studies have described the presence of several 
genomic changes as being predictors of disease progression and chemosensitivity in 
CLL.93,94 The presence of a large number of genomic alterations in 20q13-gain patients 
suggest that this new genetic entity could be associated with a more advanced disease 
in CLL, as has been suggested in non-Hodgkin lymphomas.95 The CLL patients with 
gains on 20q presented with high WBC and B-symptoms that also supports the idea 
that this abnormality could be a marker of evolution. However our study failed to 
demonstrate an association between diagnosis and progression status regarding 20q 
gain. Genomic instability could therefore be another molecular feature of CLL 
progression, as has been recently suggested.96-98 Abnormalities of chromosome 20 are 
frequently observed aberrations in cancer.99 In addition, the presence of gains on 20q 
has been associated with aggressive tumor behavior and poor clinical prognosis.100,101 
By contrast, deletions of the long arm of chromosome 20 are a common chromosomal 
abnormality associated with myeloid malignancies, and are rarely seen in lymphoid 
malignancies.99 The gain on 20q13 in CLL could be relevant to the pathogenesis and 
evolution of CLL because eleven protein-coding cancer-related genes have been 
identified in this region. It should be noted that all of these genes were upregulated in 
the CLL patients showing 20q gains in comparison with the other CLL cases. Therefore 
we suggest that 20q13.12 overexpressed genes may also be important in the evolution 
of CLL and warrant further studies.  
Gene expression profiling is a powerful tool to better understand the biology, the 
clinical outcome and molecular mechanisms implicated in chronic lymphocytic 
leukemia (CLL). Such studies have identified new prognosis markers, being ZAP-70  the 
most used in the clinical practice. Gene expression profiling demonstrated a distinct 
pattern for CLL mutated and unmutated subtypes with ZAP-70 standing out as the 
gene that most stringently separated the subsets. Several studies have demonstrated 
that ZAP70 expression in CLL correlates strongly with IgVH mutation status and it is a 
powerful prognostic factor.40,102  The study of the gene expression profile in CLL have 
given us insights into the molecular mechanisms involved in its pathogenesis by 
analyzing the impact of genomic aberrations on the expression of genes located on the 
corresponding loci.90,91,103-106 . Our data revealed an association between altered 
transcription levels and genomic imbalances in the genetic subsets of CLL, indicating 
that gene dosage might have pathogenic effects in CLL. This gene dosage effect was 
also present in CLL displayed gain on 20q.Genomic arrays have also revealed new 
insights in CLL cytogenetic subgroups defined by FISH, such as 13q deletions. Although 
deletions of 13q are often cytogenetically criptic, they represent the most frequently 
observed FISH-aberration in CLL. Deletions at 13q14 are very heterogeneous in size 
and breakpoints. Classically, when present as a solitary aberration, the del(13q) implies 
a favorable prognosis, although this statement is now under discussion and 13q- CLL 
patients are a clinically heterogeneous group.87,107 Several studies have reported that 
the extent of the deletion is associated with disease characteristics, for example 
del(13q) type II (long, involving RB1, related with disease progression) and del(13q) 
type I (short, not involving RB1, related with disease progression only when associated 
with other aberrations).90  
The present study demonstrated that the number of malignant cells carrying this 
genetic lesion strongly correlates with the disease outcome. The clinical relevance of 
the number of cells displaying a specific genetic abnormality has been recently 
demonstrated in CLL patients. Thus, the presence of more than 20% of cells with loss 
of TP53 has been associated with an adverse prognosis, while patients with less than 
20% of cells with loss of TP53 had a prognosis similar to that of the global series.100,101 
Our results showed that, according to the percentage of cells with 13q-, two 
prognostic groups could be established: the patients with a high proportion (>80%) of 
13q- cells had both a shorter overall survival than that of patients with <80% 13q- cells 
and a shorter time to first therapy. These results regarding the relationship between 
the number of 13q- cells and the outcome have been corroborated by two 
independent groups.91,103 Moreover, to better understand the molecular mechanisms 
responsible for this different outcome, a molecular characterization of these patients 
by gene expression profiling and microRNAs studies, was carried out. We 
demonstrated that several pathways were upregulated in CLL patients with higher 
percentages of 13q- cells: BCR signaling, NFkB signaling and antiapoptotic pathways 
being of special interest in CLL.  The BCR pathway is activated in poor prognosis CLL 
patients (IGHV unmutated), and the overexpression of several molecules involved in 
this pathway has been reported in advanced stages of the disease. This is consistent 
with the poor outcome observed in the CLL patients with a high load of 13q- cells. We 
also reported the overexpression of genes involved in promoting cell survival and 
antiapoptotic pathways, as well as the downregulation of several proapoptotic genes 
in these CLL patients. Therefore an imbalance between the proliferative and apoptotic 
signals could explain the lymphocytosis and the poor outcome described in these 
patients. The influence of other factors with prognostic relevance in CLL, such as IGVH 
mutational status, was discarded. Moreover, deregulation of several miRNAs was also 
observed. This is an interesting result, as several studies have recently identified 
miRNAs that could act as prognostic indicators in CLL, typically by correlating 
expression levels of these miRNA with established prognostic indicators.108   
Surprisingly, our results suggest that some of the biological characteristics of CLL 
patients with higher percentages of 13q- cells are similar to those of high-risk 
cytogenetic subgroups (17p- and 11q-), since they share the deregulation of several 
key signaling pathways, which highlights the fact that CLL patients carrying higher 
percentages of 13q- cells have more aggressive clinical course. Whether a high load of 
13q- cells has an independent prognostic value in CLL or it is a marker of progression 
remains unsolved.   
In Paper I, both FISH and aCGH revealed that 13q- was a heterogeneous group in size 
of the deletion and percentage of cells displaying the abnormality. However, we could 
not evaluate the length of the deletion in this initial cohort despite using genomic 
arrays. Correlation between FISH and aCGH was poor in these patients, we think this is 
due to (1) the lack of BAC clones in the array that map 13q14 region and (2) genetic 
aberrations are more difficult to detect using aCGH when present in lower levels, and 
approximately half of our 13q- patients had lower percentages of 13q- by FISH. In fact, 
when aCGH failed to demonstrate the presence of 13q deletion, FISH data revealed 
that most of these cases had <30%. This could justify the lack of correlation between 
both techniques in this CLL subgroup. This was not the case for the rest of FISH 
subgroups (17p-, 11q- and +12), which showed excellent correlations. Thus, in our 
initial cohort of 13q- , we evaluated the size of the deletion by the FISH probes LSI-
D13S319 probe (13q deletion) and LSI-RB probe (defining the larger 13q deletions) and 
analyzed the overall survival (Supplementary Figure 1, Paper II). This approach was 
similar to the one followed by Dal Bo et al.90 Dal Bo et al hypothesized that 13q- cases 
with a high load of 13q- cells and worse prognosis have also larger 13q deletions. 
However our analysis showed that CLL patients with lower percentages of 13q- cells by 
FISH were commonly associated with shorter deletions (not involving the RB1 locus). In 
addition, a correlation between the presence of either a short deletion or the presence 
of a low number of 13q- cells and a better outcome was present. However the patients 
with a short deletion and a high number of 13q- cells did not show a better prognosis 
than patients with high number of 13q- cells showing that the presence of high 
number of 13q- cells is always associated worst shorter survival independently of the 
deleted size on 13q- (Supplementary Figure 1, Paper II). 
Altogether, our data support the concept that patients with 13q- do not constitute 
homogeneous group and may have implications for the biology and the prognostic 
stratification of CLL.  
 
In the last part of this thesis, we present a mutational study in CLL patients by NGS 
techniques. Recent results highlight the great impact of these massively parallel 
platforms on genetics. The classical mutational studies in CLL involve immunoglobulin 
heavy chain, ATM and P53 genes. However, whole genome sequencing has provided 
new insights in the mutational status of this disease, involving several genes previously 
unrelated to CLL.74,75 One of the most striking aspects of these studies is that, despite 
the high number of patients analyzed (xxx in total), the number of genes showing 
recurrent mutations (eight in the Spanish studies74,75) and the percentages of patients 
with these mutations are very low. This confirms the concept of CLL as a very 
heterogeneous disease.  
We decided to follow a targeted resequencing strategy to capture the genes and 
regions of interest. Our selection was based on literature results (ATM, P53, PHLPP, 
PI3K) and from the results of the gene expression profiling studies (HSP90B1, E2F1, 
RAPGEF2). We detected a high number of variants, most of them annotated 
polymorphisms. Just 10% of detected variants had not been previously described. 
However, we did not reach a significant incidence, in spite of extending our series.  
Our custom-made data analysis allowed us to determine if any of the detected variants 
were related to microRNAs. Thus, we have detected the 4 bp deletion polymorphism 
(rs rs2307842) in HSP90B1 3´UTR, more specifically in the miR-223 binding site. miR-
223 is part of the microRNA signature described by Calin et al which differentiates 
IGVHmutated/ZAP70+ and IGVH/ZAP70- CLL patients.56 Moreover, miR-223 
downregulation has been associated with disease progression and shorter overall 
survival and TFT in CLL.55,86,92,109 Despite the proven implication of miR-223 expression 
in CLL prognosis, little is known on the molecular mechanisms which could be 
responsible for the poor outcome of these patients. In Paper IV we demonstrate that 
rs2307842 polymorphism alters the regulation of HSP90B1 expression by disrupting of 
the miR-223 binding site, leadind to the overexpression of this gene. Our date validate 
HSP90B1 as a target of miR-223. Moreover, our results show that CLL patients with 
rs2307842 have overexpression of HSP90B1. Interestingly, these patients usually have 
IGVH unmutated. In addition, CLL patients showing overexpression of HSP90B1 (both 
wt and with the rs2304872) share poor prognostic factors such as IGVH unmutated 
status or ZAP70 expression. HSP90 is a heat shock protein that stabilizes several 
important enzymes and antiapoptotic proteins with relevant functions in CLL REFs. 
HSP90 is commonly overexpressed in cancer, both solid and hematological types. 
Therefore HSP90 inhibitors have been proposed as a novel therapeutic option of CLL, 
particularly as their mechanism of action appears independent of mutations of ATM or 
TP53. These agents have been reported to be effective in refractory CLL cases, alone or 
in combination with classical therapies by inducing apoptosis in vitro.64,110-115 Thus our 
results open new avenues for exploring innovative pathways in CLL microRNA 










1. The use of genomic microarrays shows chromosomal alterations in 75% 
patients with CLL. Besides FISH-detected alterations, genomic microarrays 
identify new recurrent aberrations such as losses in 11q13.3, 5q13.3–q14.1, 
5q31.1 and 7q22, as well as gains in 1q21.3–q22, 11q13.3, 16q23.2–q24.2, 
6p21.31–p21.1, 20q13.12 and 10q22.3. These data confirm the heterogeneity 
of CLL.  
2. Gene expression profiling in CLL patients shows that a significant number of the 
differentially expressed genes cluster in chromosomal regions affected by the 
respective genomic imbalances. This observation suggests that changes in gene 
expression are related with copy-number alterations, which confirms the gene 
dosage effect previously described in cancer.  
3. A combined analysis of the genome and transcriptome of CLL patients reveals 
the presence of a new recurrent gain in 20q. Genomic analysis identifies the 
minimal region of gain on 20q13.12, with a size of ~2.31 Mb and present in 19% 
CLL patients. This gain is characterized by the overexpression of the genes 
located in it and a high frequency of chromosomal changes. 
4. CLL patients showing 13q deletion as a sole abnormality are a heterogeneous 
group and the number of cells displaying this aberration is related to the 
outcome of these patients. CLL patients with a higher load of 13q- cells (>80%) 
are     characterized by both a short overall survival and time to first therapy. 
5. Clonal B lymphocytes from CLL patients with a high number of 13q- losses have 
more proliferation and less apoptosis than clonal B lymphocytes from CLL 
patients with a low number of 13q- losses, due to the deregulation of several 
genes involved in these pathways, as well as microRNAS such as miR-15a, miR-
29a, miR-34a, miR-155 and miR-181b. The gene expression profile of CLL patients 
with a high number of losses in 13q is similar to the observed in high risk CLL 
patients (17p- and 11q-). Altogether, these results could justify the clinical 
differences observed between both 13q- CLL subgroups.  
6. The presence of the polymorphism rs2307842 in the 3´UTR of HSP90B1 disrupts 
the binding site for miR-223 and interferes with miR-223 function. This leads to 
the overexpression of HSP90B1 only in B lymphocytes of CLL patients.  
7. Hsa-miR-223 modulates HSP90B1 expression. These results could provide a 
plausible explanation as to why CLL patients harboring miR-223 downregulatio 
are associated with a poor outcome. A correlation between HSP90B1 and BCL2 
overexpression in CLL patients was observed. This could determine a higher 
resistance to apoptosis in CLL patients with HSP90B1 overexpression.  
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